Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry

References

• Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–260. doi:10.1093/eurheartj/ehx419. Epub 2017/09/10.
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, et al. ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. doi:10.1093/eurheartj/ehy394. Epub 2018/08/31.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. doi:10.1056/NEJMoa0904327. Epub 2009/09/01.
   PubMed Web of Science ®Google Scholar
• Tarantini G, Ueshima D, D’Amico G, Masiero G, Musumeci G, Stone GW, Brener SJ. Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: a systematic review and meta-analysis. Am Heart J. 2018;195:78–85. doi:10.1016/j.ahj.2017.09.012. Epub 2017/12/12.
   PubMed Web of Science ®Google Scholar
• Sun Y, Li C, Zhang L, Yu T, Ye H, Yu B, Tao M, Jiang J, Yan J, Wang Y, et al. Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients. Atherosclerosis. 2019;290: 52–58. doi:10.1016/j.atherosclerosis.2019.09.011. Epub 2019/10/01.
   PubMed Web of Science ®Google Scholar
• Völz S, Petursson P, Odenstedt J, Ioanes D, Haraldsson I, Angerås O, Dworeck C, Hirlekar G, Myredal A, Albertsson P, et al. Ticagrelor is not superior to clopidogrel in patients with acute coronary syndromes undergoing PCI: a report from Swedish coronary angiography and angioplasty registry. J Am Heart Assoc. 2020;9(14):e015990. doi:10.1161/JAHA.119.015990. Epub 2020/07/15.
   PubMed Web of Science ®Google Scholar
• Pavasini R, Cardelli LS, Piredda A, Tonet E, Campana R, Vitali F, Cimaglia P, Maietti E, Caglioni S, Morelli C, et al. Diastolic dysfunction, frailty and prognosis in elderly patients with acute coronary syndromes. Int J Cardiol. 2021;327:31–35. doi:10.1016/j.ijcard.2020.11.056. Epub 2020/12/04.
   PubMed Web of Science ®Google Scholar
• Badimon L, Bugiardini R, Cubedo J. Pathophysiology of acute coronary syndromes in the elderly. Int J Cardiol. 2016;222:1105–1109. doi:10.1016/j.ijcard.2016.07.205. Epub 2016/08/09.
   PubMed Web of Science ®Google Scholar
• Piccolo R, Magnani G, Ariotti S, Gargiulo G, Marino M, Santucci A, Franzone A, Tebaldi M, Heg D, Windecker S, et al. Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. EuroInterv. 2017;13(1):78–86. doi:10.4244/EIJ-D-16-00497. Epub 2017/01/04.
   PubMed Web of Science ®Google Scholar
• Chandrasekhar J, Baber U, Sartori S, Aquino M, Moalem K, Kini AS, Rao SV, Weintraub W, Henry TD, Vogel B, et al. Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Clin Res Cardiol. 2020;109(6):725–734. doi:10.1007/s00392-019-01561-4. Epub 2020/01/10.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet (London, England). 2017;390(10104):1747–1757. doi:10.1016/S0140-6736(17)32155-4. Epub 2017/09/01.
   PubMed Web of Science ®Google Scholar
• Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011;32(23):2933–2944. doi:10.1093/eurheartj/ehr422. Epub 2011/11/18.
   PubMed Web of Science ®Google Scholar
• Kim HK, Tantry US, Smith SCsJr., Jeong MH, Park SJ, Kim MH, Lim DS, Shin ES, Park DW, Huo Y, et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost. 2021;121(4):422–432. doi:10.1055/s-0040-1718729. Epub 2020/11/11.
   PubMedGoogle Scholar
• Chang CJ, Tung YC, Liu JR, Chang SH, Kuo CT, See LC. Efficacy and safety of ticagrelor vs. Clopidogrel in East Asian patients with acute myocardial infarction: a nationwide cohort study. Clin Pharmacol Ther. 2021;109(2):443–451. doi:10.1002/cpt.2011. Epub 2020/08/09.
   PubMed Web of Science ®Google Scholar
• Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome – randomized, double-blind, phase III PHILO study. Circ J. 2015;79(11):2452–2460. doi:10.1253/circj.CJ-15-0112. Epub 2015/09/18.
   PubMed Web of Science ®Google Scholar
• Kang J, Han JK, Ahn Y, Chae SC, Kim YJ, Chae IH, Hur SH, Seong IW, Chae JK, Cho MC, et al. Third-Generation P2Y12 inhibitors in East Asian acute myocardial infarction patients: a nationwide prospective multicentre study. Thromb Haemost. 2018;118(3):591–600. doi:10.1055/s-0038-1626697. Epub 2018/03/14.
   PubMed Web of Science ®Google Scholar
• Park DW, Kwon O, Jang JS, Yun SC, Park H, Kang DY, Ahn JM, Lee PH, Lee SW, Park SW, et al. Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial. Circulation. 2019;140(23):1865–1877. doi:10.1161/CIRCULATIONAHA.119.041766. Epub 2019/09/26.
   PubMed Web of Science ®Google Scholar
• Yun JE, Kim YJ, Park JJ, Kim S, Park K, Cho MS, Nam GB, Park DW. Safety and effectiveness of contemporary P2Y 12 inhibitors in an East Asian population with acute coronary syndrome: a nationwide population-based cohort study. J Am Heart Assoc. 2019;8(14):e012078. doi:10.1161/JAHA.119.012078. Epub 2019/07/17.
   PubMed Web of Science ®Google Scholar
• Ahn JH, Ahn Y, Jeong MH, Kim JH, Hong YJ, Sim DS, Kim MC, Hwang JY, Yoon JH, Seong IW, et al. Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea acute myocardial infarction registry-national institute of health. J Cardiol. 2020;75(5):478–484. doi:10.1016/j.jjcc.2019.11.003. Epub 2019/12/21.
   PubMed Web of Science ®Google Scholar
• Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi:10.1093/eurheartj/ehaa575. Epub 2020/08/30.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi:10.1093/eurheartj/ehx393. Epub 2017/09/10.
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60(16):1581–1598. doi:10.1016/j.jacc.2012.08.001. Epub 2012/09/11.
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123(23):2736–2747. doi:10.1161/CIRCULATIONAHA.110.009449. Epub 2011/06/15.
   PubMed Web of Science ®Google Scholar
• Szummer K, Montez-Rath ME, Alfredsson J, Erlinge D, Lindahl B, Hofmann R, Ravn-Fischer A, Svensson P, Jernberg T. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART registry. Circulation. 2020;142(18):1700–1708. doi:10.1161/CIRCULATIONAHA.120.050645. Epub 2020/09/02.
   PubMed Web of Science ®Google Scholar
• Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, Heestermans T, Tjon Joe Gin M, Waalewijn R, Hofma S, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet (London, England). 2020;395:1374–1381. Epub 2020/04/27.
   PubMed Web of Science ®Google Scholar
• Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012;5:680–688. Epub 2012/09/20.
   PubMed Web of Science ®Google Scholar
• Schmucker J, Fach A, Mata Marin LA, Retzlaff T, Osteresch R, Kollhorst B, Hambrecht R, Pohlabeln H, Wienbergen H. Efficacy and safety of ticagrelor in comparison to clopidogrel in elderly patients with st-segment-elevation myocardial infarctions. J Am Heart Assoc. 2019;8(18):e012530. doi:10.1161/JAHA.119.012530. Epub 2019/09/21.
   PubMed Web of Science ®Google Scholar
• Yeh RW, Kereiakes DJ, Steg PG, Cutlip DE, Croce KJ, Massaro JM, Mauri L. Lesion complexity and outcomes of extended dual antiplatelet therapy after percutaneous coronary intervention. J Am Coll Cardiol. 2017;70(18):2213–2223. doi:10.1016/j.jacc.2017.09.011. Epub 2017/10/28.
   PubMedGoogle Scholar
• Vasiljevic-Pokrajcic Z, Mickovski N, Davidovic G, Asanin M, Stefanovic B, Krljanac G, Radosavljevic-Radovanovic M, Radovanovic N, Lasica R, Milanović S, et al. Sex and age differences and outcomes in acute coronary syndromes. Int J Cardiol. 2016: 217(Suppl:S27–31):S27–S31. doi:10.1016/j.ijcard.2016.06.217. Epub 2016/07/11.
   PubMedGoogle Scholar
• Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. doi:10.1056/NEJMoa0706482. Epub 2007/11/06.
   PubMed Web of Science ®Google Scholar
• Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. Jama. 2004;291(22):2727–2733. doi:10.1001/jama.291.22.2727. Epub 2004/06/10.
   PubMed Web of Science ®Google Scholar
• Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55(23):2556–2566. doi:10.1016/j.jacc.2009.09.076. Epub 2010/06/02.
   PubMed Web of Science ®Google Scholar
• Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, Lincoff AM, Stone GW. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J. 2007;28(16):1936–1945. doi:10.1093/eurheartj/ehm194. Epub 2007/06/19.
   PubMed Web of Science ®Google Scholar
• Schoenenberger AW, Radovanovic D, Windecker S, Iglesias JF, Pedrazzini G, Stuck AE, Erne P. Temporal trends in the treatment and outcomes of elderly patients with acute coronary syndrome. Eur Heart J. 2016;37(16):1304–1311. doi:10.1093/eurheartj/ehv698. Epub 2016/01/14.
   PubMed Web of Science ®Google Scholar
• Roule V, Blanchart K, Humbert X, Legallois D, Lemaitre A, Milliez P, Beygui F, Alexandre J. Antithrombotic therapy for ACS in elderly patients. Cardiovasc Drugs and Ther. 2017;31(5–6):609–618. doi:10.1007/s10557-017-6761-y. Epub 2017/11/09.
   PubMed Web of Science ®Google Scholar
• Kang HJ, Clare RM, Gao R, Held C, Himmelmann A, James SK, Lim ST, Santoso A, Yu CM, Wallentin L, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Am Heart J. 2015;169(6):899–905.e891. doi:10.1016/j.ahj.2015.03.015. Epub 2015/06/02.
   PubMed Web of Science ®Google Scholar
• Jeong YH. “East asian paradox”: challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome. Curr Cardiol Rep. 2014;16(5):485. doi:10.1007/s11886-014-0485-4. Epub 2014/03/29.
   PubMed Web of Science ®Google Scholar
• Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, Taubert K, Smith SCsJr. Expert consensus document: world heart federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11(10):597–606. doi:10.1038/nrcardio.2014.104. Epub 2014/08/27.
   PubMed Web of Science ®Google Scholar